“In the field of prevention and treatment of agitation during the recovery period after general anesthesia, remifentanil has become an important drug due to its rapid recovery and low risk of respiratory depression. Clinical studies have shown that remifentanil significantly shortens the recovery time, reduces the incidence of agitation, and can be used in combination with other drugs to further optimize the analgesic effect and recovery quality. Future research should further explore the mechanism of action of remifentanil, optimize clinical treatment strategies, and conduct large-scale clinical trials to standardize medication regimens.”